Literature DB >> 17492591

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

Tae-Wook Chun1, J Shawn Justement, Susan Moir, Claire W Hallahan, Janine Maenza, James I Mullins, Ann C Collier, Lawrence Corey, Anthony S Fauci.   

Abstract

The persistence of latently infected resting CD4+ T cells has been clearly demonstrated in human immunodeficiency virus (HIV)-infected individuals receiving effective antiviral therapy. However, estimates of the half-life of this viral reservoir have been quite divergent. We demonstrate clear evidence for decay of this HIV reservoir in patients who initiated antiviral therapy early in infection. The half-life of this latent viral reservoir was estimated to be 4.6 months. It is projected that it will take up to 7.7 years of continuous therapy to completely eliminate latently infected resting CD4+ T cells in infected individuals who initiate antiviral therapy early in HIV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492591     DOI: 10.1086/518250

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  98 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.

Authors:  Nancie M Archin; Naveen K Vaidya; Joann D Kuruc; Abigail L Liberty; Ann Wiegand; Mary F Kearney; Myron S Cohen; John M Coffin; Ronald J Bosch; Cynthia L Gay; Joseph J Eron; David M Margolis; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 3.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 4.  Antiretroviral therapy: when to start.

Authors:  Christopher J Sellers; David A Wohl
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

5.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

Review 6.  Towards nanomedicines for neuroAIDS.

Authors:  Vidya Sagar; Sudheesh Pilakka-Kanthikeel; Ravi Pottathil; Shailendra K Saxena; Madhavan Nair
Journal:  Rev Med Virol       Date:  2014-01-07       Impact factor: 6.989

7.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

8.  No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

Authors:  Rajesh T Gandhi; Ronald J Bosch; Evgenia Aga; Mary Albrecht; Lisa M Demeter; Carrie Dykes; Barbara Bastow; Michael Para; Jun Lai; Robert F Siliciano; Janet D Siliciano; Joseph J Eron
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  Determinants of the establishment of human immunodeficiency virus type 1 latency.

Authors:  Alexandra Duverger; Jennifer Jones; Jori May; Frederic Bibollet-Ruche; Frederic A Wagner; Randall Q Cron; Olaf Kutsch
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

10.  Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.

Authors:  Silvia Baroncelli; Maria Franca Pirillo; Clementina Maria Galluzzo; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Gabriella d'Ettorre; Daniela Segala; Angela Vivarelli; Federica Sozio; Oscar Cirioni; Liliana Elena Weimer; Vincenzo Fragola; Giustino Parruti; Marco Floridia
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.